Transforming allogeneic cell therapy for patients with blood cancer, genetic diseases and autoimmune disorders
Location: United States
Employees: 51-200
Total raised: $550M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
| - | Lightspeed... | lsvp.com |
| - | DCVC | dcvc.com/ |
| - | 8VC | 8vc.com |
| 31.10.2020 | Felicis Ve... | felicis.co... |
| - | StartX | startx.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.01.2026 | Series F | $250M | - |
| 17.06.2020 | Series D | $300M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Steve | O'Hara | Investor | linkedin.c... | - | - |
Mentions in press and media 11
| Date | Title | Description |
| 13.01.2026 | Orca Bio Secures $250M for Cell Therapy Launch and Pipeline Expansion | Orca Bio, a leader in cell therapy, recently raised $250 million. This significant capital influx ensures commercial readiness for Orca-T, its lead allogeneic T-cell immunotherapy. An FDA Prescription Drug User Fee Act (PDUFA) target action... |
| 12.01.2026 | Orca Bio Raises $250M in Aggregate Funding | Orca Bio, a Menlo Park, CA-based late-stage biotechnology company developing cell therapies, raised $250M in aggregate funding. The amount consisted of $250M in new equity capital including a Series F led by Lightspeed Venture Partners from... |
| 12.01.2026 | Standard AI Acquires Pathr.ai | Standard AI, a San Francisco, CA-based technology company using computer vision and edge AI to generate a new data layer for physical retail, acquired Pathr.ai, a Mountain View, CA-based spatial intelligence company. The amount of the deal ... |
| 11.01.2026 | Orca Bio: $250 Million Funding Raised For Orca-T Launch Readiness Ahead Of April PDUFA Date | Orca Bio announced it has raised $250 million in new equity financing and expanded access to debt capital as the late-stage biotech prepares for a potential U.S. commercialization of its lead cell therapy candidate, Orca-T, with an FDA acti... |
| 08.09.2022 | Manufacturing roundup: Catalent expands in Singapore; Cambrex completes first phase of $30M NC expansion | Catalent is looking to expand its clinical supply facility in Singapore. The $2.2 million investment will grow the facility by 31,000 square feet to allow for 35 new freezers to be installed for more ultra-low tempera... |
| 08.09.2022 | Orca Bio looks to increase its cell therapy manufacturing capacity with a new facility in Sacramento | While Orca Bio has netted some major milestones, such as a $192 million Series D and a regenerative medicine advanced therapy (RMAT) designation from the FDA, the company is looking to step up things on the manufactu... |
| 21.12.2021 | Стартапы года — 2021. Выбор редакции | Содержание: Qummy OrcaBio Celly.AI ELIQ Maroo Raison Collectly Rarible Mo Tomi.ai Qummy Основатели: Евгений Писарев, Алексей Кислун, Артем Симонянц Направление: FoodTech Анастасия Марьина, Руководитель новостного отдела RB.RU: Краснодарский... |
| 17.06.2020 | Orca Bio raises $192M in Series D round for effort to replace bone marrow transplants | The funding round, which brings the total amount of money Orca has raised to nearly $300 million since it was launched in 2016, will be used to develop its pipeline of cell therapies and its manufacturing technology, which involves optimizi... |
| 17.06.2020 | Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy | Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders High precision cell therapies manufactured by Orca Bio have the pote... |
| - | Orca Bio raises $192M in Series D round for effort to replace bone marrow transplants | A company developing allogeneic cell therapies for blood cancers, autoimmune diseases and genetic diseases has raised nearly $200 million in its latest funding round. Menlo Park, California-based Orca Bio said Wednesday that it had raised $... |
Show more